SOPHiA GENETICS SA

SOPHiA GENETICS is a data-driven medicine software company founded in 2011, dedicated to establishing data-driven medicine as the standard of care for both clinical practice and life sciences research. The company's mission is to transform patient care by expanding global access to data-driven medicine. Headquartered in Rolle, Switzerland, with a significant U.S. presence in Boston, Massachusetts, SOPHiA GENETICS leverages artificial intelligence to analyze complex health data.

The company's core offering is the SOPHiA DDM™ Platform, a cloud-native software-as-a-service (SaaS) solution. This platform provides genomic, radiomic, and multimodal data analysis, generating actionable insights for healthcare professionals. It supports various clinical applications, including oncology, hereditary cancers, rare diseases, infectious diseases, cardiology, neurology, and metabolism, as well as digital pathology, transcriptomics, and copy-number variation analysis. SOPHiA GENETICS serves a global network of over 750 hospitals, laboratories, academic centers, and biopharma institutions across more than 72 countries.

In recent news, SOPHiA GENETICS confirmed leadership changes in June 2026, with co-founder Dr. Jurgi Camblong transitioning from CEO to Chairman of the Board, and Ross Muken, previously President, assuming the role of Chief Executive Officer effective July 1, 2026. The company also priced a $50 million public offering of ordinary shares in June 2026. Further demonstrating its market positioning, SOPHiA GENETICS signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center for a joint venture focused on precision oncology diagnostics. The company has been recognized for its innovation, including being named one of MIT Technology Review's 50 Smartest Companies in 2017 and Fast Company's World's Most Innovative Companies in 2023.